NEW YORK, November 18, 2025 — Leads & Copy — Anavex Life Sciences Corp. (Nasdaq: AVXL), a biopharmaceutical company focused on treatments for neurodegenerative and rare diseases, will release its fiscal year-end financial results on Tuesday, November 25, 2025.
Management will host a conference call on Tuesday, November 25, at 8:30 a.m. ET to discuss the financial results and recent developments. A question-and-answer session will follow the management’s remarks.
The live webcast of the conference call will be available on Anavex’s website. The conference call can be accessed by dialing 1-929-205-6099 for U.S. participants, using Meeting ID# 839 7768 4735 and passcode 825109. A replay will be available on Anavex’s website for up to 30 days.
Anavex Life Sciences Corp. (Nasdaq: AVXL) develops novel therapeutics for neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, such as Alzheimer’s disease, Parkinson’s disease, schizophrenia, Rett syndrome, and cancer. Its lead drug candidate, ANAVEX®2-73 (blarcamesine), has completed Phase 2a and Phase 2b/3 clinical trials for Alzheimer’s, a Phase 2 proof-of-concept study in Parkinson’s disease dementia, and Phase 2 and 3 studies in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome.
ANAVEX®2-73 is an orally available drug candidate that restores cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. Preclinical studies suggest it can halt or reverse Alzheimer’s. It has also shown anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, suggesting it could treat additional CNS disorders, including epilepsy.
The Michael J. Fox Foundation for Parkinson’s Research previously awarded Anavex a research grant to fully fund a preclinical study to develop ANAVEX®2-73 for Parkinson’s disease. The company believes ANAVEX®3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a promising clinical-stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer’s disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. In preclinical trials, ANAVEX®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation.
Readers are cautioned not to place undue reliance on forward-looking statements.
For more information, contact Anavex Life Sciences Corp. Research & Business Development at 1-844-689-3939 or info@anavex.com. Investors can contact Andrew J. Barwicki at 516-662-9461 or andrew@barwicki.com.
Source: Anavex Life Sciences Corp.
